BioMarin Pharmaceutical Inc. has announced its intention to acquire Amicus Therapeutics, Inc. to enhance its portfolio and capabilities in developing therapies for rare diseases, supported by a financial structure that includes the issuance of senior unsecured notes and secured term loans.

Information on the target

BioMarin Pharmaceutical Inc. is a prominent biotechnology company based in San Rafael, California, specializing in the development of innovative therapies for rare genetic diseases. Established in 1997, BioMarin has built a robust portfolio that includes eight commercial products and a strong pipeline of clinical and preclinical candidates. The company is dedicated to leveraging genetic science to create transformative medicines that significantly improve the lives of patients suffering from genetically defined conditions.

Recently, BioMarin announced its intention to acquire Amicus Therapeutics, Inc., a company known for its focus on developing treatments for rare diseases. This acquisition is expected to enhance BioMarin's capabilities and expand its therapeutic offerings, aligning with its mission to address unmet medical needs in the rare disease space.

Industry overview in the target’s specific country

The biotechnology industry in the United States is one of the most advanced and dynamic sectors globally, characterized by rapid innovation and significant investment in research and development. The U.S. is home to numerous leading biotech firms, academic in